Русский / English
Enter the query
News
Press Center
phone: +7 495 785 29 07
fax: +7 499 230 32 94
press@interros.ru
Contacts
06.08.2018
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
More Topics Petrovax Pharm
16.07.2018
The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.
More Topics Petrovax Pharm / vaccine prophylaxis / quadrivalent vaccine
11.06.2018
The rating is put together annually by Extel, a British company that studies the global investment climate.
More Topics Norilsk Nickel
15.03.2018
On March 15, 2018, Interros Group acquired a 2.1% stake in Norilsk Nickel from Crispian Investments Limited – a subsidiary company of the Millhouse Group. To date, the Interros Group holds 32.9% shares in OJSC MMC Norilsk Nickel.
More Topics Norilsk Nickel / Interros
09.02.2018
The JV aims at becoming one of the world’s largest producers of platinum group metals with a target annual production volume of approximately 70-100 tons of PGMs.
More Topics Norilsk Nickel